Hyperfine 2025 Q3 Earnings Sequential Revenue Growth Amid Widening Net Loss

Hyperfine (HYPR) reported Q3 2025 earnings on Nov 14, 2025, with revenue of $3.44 million, down 5.7% year-over-year but up 27% sequentially. The stock surged 12.75% in the latest session, though it fell 47.73% month-to-date. Guidance for Q4 revenue of $5–$6 million represents a 60–67% sequential increase, signaling optimism despite a 6.7% wider net loss.

Revenue

Device sales accounted for the majority at $2.89 million, with service revenue contributing $546,000, totaling $3.44 million in total sales. The decline from $3.64 million in Q3 2024 reflects market challenges, though sequential growth highlights product adoption momentum.

Earnings/Net Income

Hyperfine maintained an EPS of $-0.14, consistent with Q3 2024, while the net loss expanded to $11.02 million, a 6.7% increase from $10.33 million. Persistent losses over five years underscore financial pressures, despite gross margin improvements and cost discipline.

Price Action

The stock price surged 12.75% during the latest trading day and 7.48% in the week, but a 47.73% monthly decline highlights volatility. Post-earnings reactions remain mixed, with short-term optimism clashing against broader bearish trends.

CEO Commentary

Maria Sainz highlighted a 27% sequential revenue boost driven by the next-gen Swoop system and Opti AI software, achieving 54% gross margins. The CEO emphasized “mainstream adoption” readiness, bolstered by $20 million in October fundraising. Strategic priorities include U.S. hospital deals, neurology office partnerships, and international expansion, with cash runway extended to mid-2027.

Guidance

CFO Brett Hale projected Q4 2025 revenue of $5–$6 million (60–67% sequential growth) and full-year revenue of $13–$14 million. Gross margin is expected to reach 49–51% in 2025, up 430 bps year-over-year. Cash burn for 2025 is forecast at $29–31 million, a 22% reduction from 2024, supported by $20 million in October financing.

Additional News

Hyperfine secured CE and UKCA approvals for Opti AI software, enabling European and UK deployments. The company also announced the first installation of its Swoop system at Norway’s Stavanger University Hospital, marking its entry into Nordic markets. Additionally, Hyperfine priced a $17.5 million public offering in October 2025, with proceeds allocated to commercial expansion and R&D.

Post-Earnings Price Action Review

The stock’s 12.75% daily surge followed a strong earnings call emphasizing sequential revenue growth and margin expansion. However, the month-to-date 47.73% decline reflects broader market skepticism, with analysts noting risks from cash burn and unproven adoption rates. While short-term optimism persists due to improved guidance and product launches, long-term concerns about profitability and competition remain. The recent $20 million fundraising provides near-term liquidity but does not resolve structural challenges. Investors are cautiously optimistic, balancing near-term momentum with the company’s history of losses and high burn rates.

Financial Highlights

• Q3 2025 Revenue: $3.44M (down 5.7% YoY, up 27% QoQ)

• Gross Margin: 53.8% (record high)

• Net Loss: $11.02M (6.7% increase)

• Cash Burn: $29–31M for 2025 (22% lower YoY)

• October Financing: $20.1M raised, extending cash runway to mid-2027

Strategic Priorities

Hyperfine is focusing on three verticals: U.S. hospitals (multi-unit deals), neurology offices (Neuro Net partnerships), and international markets (CE/UKCA approvals, France procurement). The company aims to leverage its next-gen Swoop system and Opti AI software to drive adoption across diverse care settings.